Formulated to help protect, cleanse and moisturize the skin as part of an effective skincare regimen for indications such as pressure injuries, incontinence-associated dermatitis (IAD) or moisture-associated skin damage (MASD)1
The SECURA Skincare range is suitable for use in pressure injury prevention and the treatment of various skin conditions.
Precautions
For external use only. If irritation occurs, consult a physician.
Warnings
For external use only. Avoid contact with eyes. Not to be applied over deep or puncture wounds, infections or lacerations. If condition worsens or does not improve within 7 days, consult a doctor. Keep this and all drugs out of the reach of children. If swallowed, get medical help or contact a Poison Control Center immediately.
Disclaimer
For detailed product information, including indications for use, ingredients, directions, contraindications, precautions, warnings and/or important safety information, please consult each product’s package labelling, Instructions for Use (IFU) and/or drug facts prior to use.
Recall and Complaints
Customer will provide such support and assistance as S+N may reasonably request in the event of a general or limited voluntary or mandatory recall of the Product(s). Customer shall promptly report any complaint in respect of the Products to complaints@smith-nephew.com.
1. European Pressure Ulcer Advisory Panel, National Pressure Injury Advisory Panel and Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers/Injuries: Clinical Practice Guideline. Emily Haesler (Ed.). EPUAP/NPIAP/PPPIA: 2019.
2. Smith+Nephew 2020. Internal report. PSS415.
3. Monograph Title 21 CFR Part 347 - Skin Protectant Drug Products for Over the Counter Human Use Final Monograph 06/2003.
4. Fiers, S.A. OWM, vol 43, no 3, April 1996, 32-42.
5. Scheps M.H. Home Health Care Consultant, vol 3l NO 1, Jan-Feb 1996, 37-39.
6. Smith+Nephew 2019. Internal report. RD/19/026/v2.
7. Hilltop Research 2007. Internal report. 07-128386-111.
8. Nursing Care Moisturizing Cream Formulation (F-50). 2009.
9. Evaluation of Cumulative Irritation Potential in Humans (21-day), Report # 94-2404-72A, Hill Top Research.
10. Monograph Title 21 CFR Part 347 - Skin Protectant Drug Products for Over the Counter Human Use final Monograph 06/2003.
11. Brett, D. The justification of Secure Anti-Fungal Extra Thick Cream formulated to not wash away even in severe cases of diarrhea and soothing and gentle to the skin. 2017.
12. Title 21 CFR, Part 333, SubpartC - Topical Antifungal Drug Products.
13. Smith+Nephew 2020. The justification of pH buffered claim for the total body foam cleanser (TBFCI). Internal report.
14. Microbiotest report: Chlorhexidine Gluconate compatibility Evaluation of Skin Treatment Products. 2020.
Text